SELLAS Life Sciences Group Inc (NAS:SLS) Stock News, Headlines & Updates
SELLAS Life Sciences Group Inc Stock News from GuruFocus
- 1
Aug 13, 2024
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Marketwired • 4:00pm
Aug 06, 2024
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
Marketwired • 8:00am
Jul 31, 2024
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
Marketwired • 8:00am
Jul 16, 2024
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
Marketwired • 9:00am
Jul 08, 2024
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
Marketwired • 8:00am
Jun 24, 2024
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
Marketwired • 9:00am
Jun 17, 2024
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
Marketwired • 9:00am
Jun 10, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news